What are tumour markers?

• Introduction
• Abortion
• Amenorrhoea
• Birth Control
• Bladder Symptoms
• Cancer in Women
• What is cancer?
• Cancer Staging
• Prevalence
• Familial Cancer
• Symptoms, Signs, Diagnosis
• Prevention
• Screening
• Emotional Effects
• Counselling
• Personality and Outcome
• Holistic Approach
• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Endometrial Cancer
• Vulva, Vagina, Fall.Tubes
• Treatments
• Mortality
• Support Groups
• Childbirth
• Children and Teenagers
• Diet / Weight Loss
• Dysmenorrhoea
• Endometriosis
• Fibroids
• HRT
• Hirsutism
• Hysterectomy
• Infections
• Infertility
• Medication Drugs
• Menopause
• Menorrhagia
• Miscarriage
• Painful Sex
• Pap Smear Test
• PCOS
• Pelvic Pain
• PMS
• Postpartum
• Pregnancy
• Self Esteem
• Sexual Problems
• Vaginal Discharge
• Vaginal Prolapse
• Vulval Symptoms

Underperforming Family Website?

 

 

 

Visit

KeywordSEOPro.com - SEO Keyword Tool & SEO Tips

Now

 

Promote Your

Family Website

 

Improve Your Business Income

 

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91.

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

Duffy MJ,Bonfrer JM,Kulpa J,Rustin GJ,Soletormos G,Torre GC,Tuxen MK,Zwirner M.

Department of Nuclear Medicine, St Vincent's University Hospital, Dublin, Ireland. michael.j.duffy@ucd. Ie CA125 is currently the most widely used tumor marker for ovarian epithelial cancer. The aim of this article is to provide guidelines for the routine clinical use of CA125 in patients with ovarian cancer. Due to lack of sensitivity for stage I disease and lack of specificity, CA125 is of little value in the detection of early ovarian cancer. At present, therefore, CA125, either alone or in combination with other modalities, cannot be recommended for screening for ovarian cancer in asymptomatic women outside the context of a randomized controlled trial. Preoperative levels in postmenopausal women, however, may aid the differentiation of benign and malignant pelvic masses. Serial levels during chemotherapy for ovarian cancer are useful for assessing response to treatment. Although serial monitoring following initial chemotherapy can lead to the early detection of recurrent disease, the clinical value of this lead-time is unclear. CA125 is the ovarian cancer marker against which new markers for this malignancy should be judged.

Please click on the required question.

• 1 What is cancer (malignancy)
• 2 What is meant by cancer staging?
• 3 How prevalent is cancer?
• 4 How prevalent are womens' cancers?
• 5 What causes cancer?
• 6 Is cancer a hereditary condition?
• 7 How can gynaecological cancer present?
• 8 How can we reduce the risks of the womens' cancers?

   

  Reducing the Risks of Womens' Cancers.

• 9 What are screening tests?
• 10 What are the reactions to a diagnosis of cancer?
• 11 Is there a place for counselling when cancer is diagnosed?
• 12 Can personality alter the prognosis?
• 13 Is the incidence of deaths from the female cancers changing?
• 14 Is there a place for a holistic approach to cancer?

   

  Cancer of the Cervix.

• 15 How prevalent is cervical cancer?
• 16 What causes cervical cancer?
• 17 How long an interval should there be between cervical screening (smear) (PAP) tests?
• 18 Is there any evidence that cervical screening can reduce the incidence of cervical cancer?
• 19 Will pre-malignant changes of the cervix invariably lead to cancer?

   

  Endometrial Cancer (Uterus)

• 20 What causes endometrial cancer?
• 21 Are there screening tests for endometrial cancer?
• 22 How does endometrial cancer present?
• 22a How can endometrial cancer be prevented?
• 22b How can endometrial cancer be treated?

  Cancer of the Ovary.

• 23 How does ovarian cancer present?
• 24 How prevalent is ovarian cancer?
• 25 What are tumour markers?
• 26 Can we screen for ovarian cancer?
• 27 What is the relationship between infertility and ovarian cancer?
• 28 Can treatment of infertility increase the risk of ovarian cancer?
• 29 What is the relationship between oral contraception and cancer?
• 30 Can ovarian cancer be prevented?
• 31 I use talcum power. Could this increase my risk of developing ovarian cancer?

   

  The Treatment Of Womens' Cancers

• 32 Can we predict the course of a cancer?
• 33 What treatment options are available for gynaecological cancer?
• Q32.33c What treatment options are available for ovarian cancer?

  Cancer of the Vulva, Vagina and Fallopian Tube

• 34 How prevalent are malignant conditions of the vulva, vagina and Fallopian tubes?

  Breast Cancer

• 35 What is the incidence of breast cancer?
• 35 ?What is the cause of breast cancer?
• 35a What are the advantages of breast cancer screening - mammography - mammograms?
• 36 How often should breast screening be carried out?
• 37 Are there any problems having a mammogram?
• 38 Should I check myself for breast lumps?
• 39 One of my family developed cancer of the breast. Am I at increased risk?
• 40 We have a family tendency towards developing breast / ovarian cancer. Are there any genetic tests to find out if I am at increased risk?
• 41 What happens if a mammogram shows an abnormality?
• 42 What are the advantages and disadvantages of tamoxifen in the management of breast cancer?
• 42a Breast Cancer Treatment - What is available?
• 43 What is the relationship between breast cancer and the pill?

  Web sites and Support Groups

• 44 Are there any support groups?
• 44 Are there any support groups?
• 45 Support Groups.
• 46 Breast Cancer Support Groups
• 47 Ovarian Cancer Support Groups
• 48 Endometrial Cancer Support Groups
• 49 Cervical Cancer Support Groups
  
  
  

  
  
  

  Thank you for choosing to visit us.

  
  

  This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.

  I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.